Literature DB >> 11409880

The imidazoline RX871024 stimulates insulin secretion in pancreatic beta-cells from mice deficient in K(ATP) channel function.

A M Efanov1, M Høy, R Bränström, S V Zaitsev, M A Magnuson, S Efendic, J Gromada, P O Berggren.   

Abstract

Effects of the imidazoline compound RX871024 on cytosolic free Ca(2+) concentration ([Ca(2+)]i) and insulin secretion in pancreatic beta-cells from SUR1 deficient mice have been studied. In beta-cells from wild-type mice RX871024 increased [Ca(2+)]i by blocking ATP-dependent K(+)-current (K(ATP)) and inducing membrane depolarization. In beta-cells lacking a component of the K(ATP)-channel, SUR1 subunit, RX871024 failed to increase [Ca(2+)]i. However, insulin secretion in these cells was strongly stimulated by the imidazoline. Thus, a major component of the insulinotropic activity of RX871024 is stimulation of insulin exocytosis independently from changes in K(ATP)-current and [Ca(2+)]i. This means that effects of RX871024 on insulin exocytosis are partly mediated by interaction with proteins distinct from those composing the K(ATP)-channel. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11409880     DOI: 10.1006/bbrc.2001.5068

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Identification of the monomeric G-protein, Rhes, as an efaroxan-regulated protein in the pancreatic beta-cell.

Authors:  Sue L F Chan; Lara K Monks; Hongwei Gao; Pamela Deaville; Noel G Morgan
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

2.  Pharmacological stimulation and inhibition of insulin secretion in mouse islets lacking ATP-sensitive K+ channels.

Authors:  A Szollosi; M Nenquin; J C Henquin
Journal:  Br J Pharmacol       Date:  2010-01-28       Impact factor: 8.739

3.  alpha2A-adrenoceptor antagonism increases insulin secretion and synergistically augments the insulinotropic effect of glibenclamide in mice.

Authors:  V Fagerholm; M Scheinin; M Haaparanta
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.